相关实验视频

Updated: Jan 16, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

蒂尔泽帕提德与SGLT2抑制剂对MASLD:一个多机构倾向性得分匹配的队列研究

Jheng-Yan Wu1,2, Yu-Min Lin3, Wan-Hsuan Hsu4

  • 1Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.

Hepatology international
|January 14, 2026
PubMed
概括

与SGLT2抑制剂相比,提尔泽帕提德 (TZP) 显著降低了代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的死亡率,心血管事件和肝脏结果. 这种现实世界的证据表明,TZP可能是MASLD管理的优越治疗选择.

关键词:
心血管方面的结果.肝脏疾病是一种肝脏疾病.马斯尔德 马斯尔德是什么意思死亡率 死亡率 死亡率这就是SGLT2i.蒂尔泽帕提德是什么意思

更多相关视频

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
841